UK markets closed
  • NIKKEI 225

    26,748.14
    -253.38 (-0.94%)
     
  • HANG SENG

    20,112.10
    -357.96 (-1.75%)
     
  • CRUDE OIL

    109.88
    -0.41 (-0.37%)
     
  • GOLD FUTURES

    1,864.60
    +16.80 (+0.91%)
     
  • DOW

    31,833.53
    -46.71 (-0.15%)
     
  • BTC-GBP

    23,485.08
    -661.01 (-2.74%)
     
  • CMC Crypto 200

    654.89
    -0.93 (-0.14%)
     
  • ^IXIC

    11,270.26
    -265.01 (-2.30%)
     
  • ^FTAS

    4,126.79
    -23.49 (-0.57%)
     

Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

REDWOOD CITY, Calif., December 29, 2021--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating in the upcoming 40th Annual J.P. Morgan Healthcare Conference.

Guardant Health’s management is scheduled to present on Monday, January 10 at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: www.guardanthealth.com.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary tests, vast data sets and advanced analytics. The Guardant Health oncology platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has commercially launched Guardant360®, Guardant360 CDx, Guardant360 TissueNext™, Guardant360 Response™, and GuardantOMNI® tests for advanced stage cancer patients, and Guardant Reveal™ for early-stage cancer patients. These tests fuel development of its LUNAR screening program, which aims to address the needs of asymptomatic individuals eligible for cancer screening.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211229005020/en/

Contacts

Investor Contact:
Carrie Mendivil
investors@guardanthealth.com

Media Contact:
Michele Rest
press@guardanthealth.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting